Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 501–600 of 1,014
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 88
RetractedHygum, K., Starup‐Linde, J., & Langdahl, B. L. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.05.001 · Cited by 94
Kim, S. G., Kim, D. M., Woo, J.-T., Jang, H. C., Chung, C. H., Ko, K. S., Park, J. H., Park, Y. S., Kim, S. J., & Choi, D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092843 · Cited by 83
Type 2 Diabetes Prevention: A Review
Ahmad, L. A., & Crandall, J. P. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.2.53 · Cited by 86
Treating type 2 diabetes: how safe are current therapeutic agents?
Philippé, J., & Raccah, D. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01980.x · Cited by 98
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Berhan, A., & Barker, A. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-58 · Cited by 85
Forst, T., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 85
Pharmacogenetics of metformin response: a step in the path toward personalized medicine
Reitman, M. L., & Schadt, E. E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32133 · Cited by 85
Diabetes mellitus: new drugs for a new epidemic
Nicholson, G., & Hall, G. M. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer120 · Cited by 98
Kanat, M., DeFronzo, R. A., & Abdul-Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 82
Wu, C., Zhao, Y. L., Zhang, Y., Yang, Y., Su, W., Yang, Y., Sun, L., Zhang, F., Yu, J., Wang, Y., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.011 · Cited by 94
Varney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 90
Glucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?
van Raalte, D. H., & Diamant, M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70012-2 · Cited by 101
Gupta, D., Kono, T., & Evans‐Molina, C. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01299.x · Cited by 97
Diabetes mellitus, bone mineral density, and fracture risk
Strotmeyer, E. S., & Cauley, J. A. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f1cba3 · Cited by 83
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Ahren, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1944 · Cited by 83
Chan, S. P., & Colagiuri, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.002 · Cited by 94
Weight Beneficial Treatments for Type 2 Diabetes
Meneghini, L. F., Orozco‐Beltrán, D., Khunti, K., Caputo, S., Damçi, T., Liebl, A., & Ross, S. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1074 · Cited by 84
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Vella, V., Nicolosi, M. L., Giuliano, S., Bellomo, M., Belfiore, A., & Malaguarnera, R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00031 · Cited by 93
Cicero, A. F. G., Tartagni, E., & Ertek, S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31622 · Cited by 81
Bergenstal, R., Lewin, A., Bailey, T., Chang, D., Gylvin, T., Roberts, V., & for the NovoLog Mix-vs.-Exenatide Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 83
Rosiglitazone RECORD study: glucose control outcomes at 18 months
Home, P. D., Jones, N. P., Pocock, S. J., Beck‐Nielsen, H., Gomis, R., Hanefeld, M., Komajda, M., Curtis, P., & for the RECORD Study Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02160.x · Cited by 83
Self-citationBrownstein, J. S., Murphy, S. N., Goldfine, A. B., Grant, R. W., Sordo, M., Gainer, V., Colecchi, J. A., Dubey, A., Nathan, D. M., Glaser, J. P., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1506 · Cited by 83
Update on Medications With Adverse Skeletal Effects
Davidge-Pitts, C. J., & Kearns, A. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0636 · Cited by 89
Managing Type 2 Diabetes: Going Beyond Glycemic Control
STOLAR, M. W., Hoogwerf, B. J., Boyle, P. J., Gorshow, S. M., & Wales, D. O. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s5-b.1 · Cited by 98
Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis
Colmers, I. N., Bowker, S. L., & Johnson, J. A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.06.003 · Cited by 81
Meneilly, G. S., Knip, A., & Tessier, D. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.045 · Cited by 91
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Hollander, P. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 80
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 103
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 92
Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., Pearson, E. R., Hattersley, A. T., Shields, B. M., Jones, A. G., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13687 · Cited by 85
Self-citationThe Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 97
Smushkin, G., & Vella, A. V. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.008 · Cited by 106
Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study
Martínez-Laguna, D., Tebé, C., Javaid, M. K., Nogués, X., Arden, N., Cooper, C. C., Díez‐Pérez, A., & Prieto‐Alhambra, D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2986-9 · Cited by 83
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 79
Antidiabetic therapy effects on bone metabolism and fracture risk
Montagnani, A., & Gonnelli, S. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12077 · Cited by 80
Marrow Adipocytes: Origin, Structure, and Function
de Paula, F. J. A., & Rosen, C. J. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034513 · Cited by 83
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Bae, J., Park, T., Kim, H., Lee, M., & Soo, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0272 · Cited by 89
Erdmann, E., & Wilcox, R. G. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm529 · Cited by 79
Lablanche, S., Cottet-Rousselle, C., Lamarche, F., Benhamou, P.-Y., Halimi, S., Leverve, X., & Fontaine, E. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.15 · Cited by 80
Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin
Aston‐Mourney, K., Proietto, J., Morahan, G., & Andrikopoulos, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0930-2 · Cited by 89
Alvarez-Guisasola, F., Yin, D. D., Nocea, G., Qiu, Y., & Mavros, P. (2010) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-8-86 · Cited by 78
Donnelly, L. A., Morris, A. D., & Pearson, E. R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00973.x · Cited by 78
Arslanian, S. A., Kim, J. Y., Nasr, A., Bacha, F. F., Tfayli, H. M., Lee, S., & Toledo, F. G. S. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12562 · Cited by 82
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 82
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0030-9 · Cited by 88
Kawashima, Y., Fritton, J. C., Yakar, S., Epstein, S., Schaffler, M. B., Jepsen, K. J., & LeRoith, D. (2008) · Bone · doi:10.1016/j.bone.2008.12.012 · Cited by 78
Florez, J. C., Jablonski, K. A., Taylor, A., Mather, K. J., Horton, E. S., White, N. H., Barrett-Connor, E. L., Knowler, W. C., Shuldiner, A. R., & Pollin, T. I. (2012) · Diabetes Care · doi:10.2337/dc11-2301 · Cited by 78
Gilbert, M. P., Marre, M., Holst, J. J., Garber, A. J., Baeres, F. M. M., Thomsen, H. F., & Pratley, R. E. (2015) · Endocrine Practice · doi:10.4158/ep15758.or · Cited by 81
The effect of thiazolidinediones on BMD and osteoporosis
McDonough, A. K., Rosenthal, R. S., Cao, X., & Saag, K. G. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0920 · Cited by 79
ß‐cell function and anti‐diabetic pharmacotherapy
Prato, S. D., Bianchi, C., & Marchetti, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.770 · Cited by 108
Yang, Y., Qiu, W., Xiao, J., Sun, J., Ren, X., & Jiang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05060-7 · Cited by 85
Schweizer, A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2503 · Cited by 92
Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
Lachin, J. M., Viberti, G. C., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Holman, R. R., & Kahn, S. E. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09291010 · Cited by 81
Self-citationLiu, R., Wang, H., Xu, B., Chen, W., Turlova, E., Dong, N., Sun, C. L. F., Lu, Y., Fu, H., Shi, R., et al. (2016) · Diabetes · doi:10.2337/db15-1737 · Cited by 83
Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences
Russo, G. T., Giandalia, A., Romeo, E. L., Morabito, N., Muscianisi, M., Ruffo, M. C., Catalano, A., & Cucinotta, D. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1615735 · Cited by 86
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
“A suggestion of increase in bone fractures in women associated with the use of both rosiglitazone and pioglitazone already emerged from the large intervention trials ADOPT [18] and PROactive [101].”
BackgroundBailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
Glycemic control and fracture risk in elderly patients with diabetes
Conway, B. N., Long, D. M., Figaro, M. K., & May, M. E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.009 · Cited by 76
Regulation of brown fat by AMP-activated protein kinase
van Dam, A. D., Kooijman, S., Schilperoort, M., Rensen, P. C. N., & Boon, M. R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.003 · Cited by 86
Controversies in gestational diabetes
Nolan, C. J. (2010) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.004 · Cited by 96
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
Van Wagner, L. B., & Rinella, M. E. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11403809 · Cited by 77
Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus
Azuma, K., Heilbronn, L. K., Albu, J., Smith, S. R., Ravussin, É., & Kelley, D. E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00394.2006 · Cited by 99
Riedel, A. A., Heien, H., Wogen, J., & Plauschinat, C. A. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1102 · Cited by 77
Effects of SGLT2 inhibitors on cardiovascular outcomes
Foote, C., Perkovic, V., & Neal, B. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441190 · Cited by 77
Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes
Barnett, A. H., Cradock, S., Fisher, M., Hall, G., Hughes, E., & Middleton, A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02332.x · Cited by 77
Potential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, C. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4039 · Cited by 74
Strojek, K., Yoon, K.-H., Hruba, V., Sugg, J., Langkilde, A. M., & Parikh, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 74
Stunes, A. K., Westbroek, I., Gustafsson, B. I., Fossmark, R., Waarsing, J. H., Eriksen, E. F., Petzold, C., Reseland, J. E., & Syversen, U. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-11 · Cited by 76
The right place for metformin today
Schernthaner, G., & Schernthaner, G.-H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107946 · Cited by 87
Diabetes mellitus, hyperglycaemia and cancer
Simon, D., & Balkau, B. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.04.001 · Cited by 82
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
Berkowitz, S. A., Krumme, A. A., Avorn, J., Brennan, T., Matlin, O. S., Spettell, C. M., Pezalla, E. J., Brill, G., Shrank, W. H., & Choudhry, N. K. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5294 · Cited by 68
Consensus on the key characteristics of metabolism disruptors
Merrill, M. A. L., Smith, M. T., McHale, C. M., Heindel, J. J., Atlas, E., Cave, M. C., Collier, D. N., Guyton, K. Z., Koliwad, S. K., Nadal, Á., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01059-8 · Cited by 84
Umamaheswaran, G., Praveen, R. G., Damodaran, S. E., Das, A. K., & Adithan, C. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0322-5 · Cited by 74
Styner, M., Sen, B., Xie, Z., Case, N. D., & Rubin, J. E. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22793 · Cited by 87
Barrett, T. G., Jalaludin, M. Y., Turan, S., Hafez, M., Shehadeh, N., & Panel, O. B. O. T. N. N. P. T. 2. D. G. E. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12953 · Cited by 74
The role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 79
Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities
Stroope, C., Nettersheim, F. S., Coon, B. G., Finney, A. C., Schwartz, M. A., Ley, K. F., Rom, O., & Yurdagul, A. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01015-w · Cited by 77
Efficacy and safety of incretin-based therapies: Clinical trial data
White, J. R. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09079 · Cited by 80
Cardiac safety profile of rosiglitazone
Mannucci, E., Monami, M., Bari, M. D., Lamanna, C., Gori, F., Gensini, G. F., & Marchionni, N. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.01.064 · Cited by 76
Walford, G. A., Davis, J., Warner, A. S., Ackerman, R. J., Billings, L. K., Chamarthi, B., Fanelli, R. R., Hernandez, A. M., Huang, C., Khan, S. Q., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.07.003 · Cited by 73
Karalliedde, J. J., & Buckingham, R. E. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00002 · Cited by 76
Type 2 diabetes in younger adults: the emerging UK epidemic
Wilmot, E. G., Davies, M. J., Yates, T., Benhalima, K., Lawrence, I. G., & Khunti, K. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.100917 · Cited by 72
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 75
Conte, C., & Secchi, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1137-8 · Cited by 81
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 60
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12302 · Cited by 71
Ohshima, K., Mogi, M., Jing, F., Iwanami, J., Tsukuda, K., Min, L., Ogimoto, A., Dahlöf, B., Steckelings, U. M., Unger, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048387 · Cited by 72
Zeng, Z., Huang, S., & Sun, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00922-x · Cited by 78
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 83
Lin, Y., & Sun, Z. (2012) · Endocrinology · doi:10.1210/en.2012-1091 · Cited by 71
Blonde, L., Pencek, R., & MacConell, L. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0171-2 · Cited by 72
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 75
Leonard, C. E., Han, X., Brensinger, C. M., Bilker, W. B., Cardillo, S., Flory, J., & Hennessy, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4337 · Cited by 78
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
Donnelly, L. A., Dennis, J., Coleman, R. L., Sattar, N. A., Hattersley, A. T., Holman, R. R., & Pearson, E. R. (2020) · Diabetes Care · doi:10.2337/dc20-1104 · Cited by 82
Self-citation
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.